Overview
- Description
XENOTHERA is a clinical stage biotech at the top of innovation, which creates new therapeutic modes in numerous domains. Xenothera's patented technological platform is built on a double expertise of immunology and genetic engineering. It develops innovative approaches in immunotherapy by marketing Glyco-Humanized Polyclonal Antibodies (GH-pAb). Our antibodies are engineered to display high therapeutic properties.
XENOTHERA’s platform ensures short-time development from animal genetics, choice of the immunogen, selection and purification of antibodies, and access to market authorization in accelerated timescale. Within less than 5 years, XENOTHERA has brought to clinic its first product LIS1, a novel induction treatment in Solid Organ Transplantation, addressing a $1Bn market. It has also established in vivo Proof-of-Concept in Immuno-Oncology and Multi-Drug Resistant infections.
- Website
- Invested amount
EUR 9 999 930.6
- Founded
2014
- Project
- Press Release
- Country
- France
- Theme
- Biotechnology